+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-08-09Number of Pages: 175

Alzheimer’s Drugs Market (Drug class - Cholinergic, Memantine, and Combined Drug; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Alzheimer’s Drugs Market: Snapshot

Alzheimer’s disease is a neurodegenerative disorder that causes slow decline in abilities such as thinking, reasoning, and routine daily activities, alongside memory loss. This may lead to planning or solving problems, poor judgment, lack of social activities, and personality and mood changes, which are considered the most common symptoms of Alzheimer’s disease. Symptoms of Alzheimer’s disease generally begin to appear in patients in their mid-sixties. As per World Alzheimer’s report, one new case of AD is registered every 3.2 seconds. The death burden from Alzheimer’s disease is increasing in all developed and growing countries in recent years following growth of the geriatric demographic. There is no cure for Alzheimer’s yet but a number of marketed drug help improve symptoms. There is no modified disease drug in the market, resulting in high unmet need for the Alzheimer’s drug market.

alzheimers drugs market

North America Dominates Global Alzheimer’s Market due to Widespread Awareness

The global Alzheimer’s drug market is segmented on the basis of drug class type, distribution channel, and region. Based on drug class, the Alzheimer’s drug market has been segmented into cholinergic, memantine, combined drugs, others. Memantine dominated the global Alzheimer’s drugs market in 2016 due to patent expiry of major products and the limited number of Alzheimer’s drugs. The memantine segment is expected to remain dominant through the forecast period. The cholinergic segment is expected to have a considerable share in the global Alzheimer’s drugs market and is likely to expand at a strong CAGR during the forecast period due to the limited availability of effective drug classes globally. Combined drug class sales increased in 2016 compared to previous years, and this segment is anticipated to expand at a significant CAGR during forecast periods.

The global Alzheimer’s drugs market is segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy, and online sales. The hospital pharmacy segment has held the largest share in the Alzheimer’s drug market in 2016 due to the growing demand for Alzheimer’s treatment in hospitals. The hospital pharmacy segment is projected to expand at a significant CAGR during forecast period. The online sales segment is expected to gain a stronger market share during the forecast period, due to the growing use of mobile-based applications for ordering the medicines.

On the basis of geography, the global Alzheimer’s drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held the largest share in the global Alzheimer’s drugs market in 2016 due to the high number of Alzheimer’s patients and the growing awareness about the disease in the region. The North America Alzheimer’s drugs market was valued at US$1.7 bn in 2017 and is likely to rise to more than US$3 bn by 2025. The Asia Pacific market, meanwhile, is likely to exhibit a robust 8.6% CAGR between 2017 and 2025. Latin America and the Middle East and Africa are relatively smaller markets for Alzheimer’s drugs. However, the Brazil Alzheimer’s drugs market is expected to grow at a significant CAGR in forecast period and the country is likely to dominate the Alzheimer’s drugs market in Latin America.

Limited Number of Branded Drugs Holding Alzheimer’s Market Back

The key market drivers for global Alzheimer’s market are the increasing prevalence of the disease. Increasing awareness has played a key role in the growth of the global Alzheimer’s drug market, but in several developing regions the treatment facilities remain behind the time due to the high prices of advanced drugs. High pricing and lack of limited branded drugs are thus the key restraints for the Alzheimer’s drug market. Success in developing effective drugs at low costs is thus the major research strategy of players in the Alzheimer’s drugs market.

Allergan plc and Novartis AG dominated the global Alzheimer’s drugs market in 2016. Their global market presence and acquisition of leading brands have contributed to their dominance. Other key players in the global Alzheimer’s drugs market include Eisai Co Ltd, H Lundbeck A/S, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co Ltd, Merz Holding GmbH & Co KG, and Johnson & Johnson.

Chapter 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Research Highlights

Chapter 2 Assumptions and Research Methodology 
2.1 Assumptions
2.2 Research Methodology

Chapter 3 Executive Summary
3.1 Alzheimer’s Drugs Market Snapshot, 2016
3.2 Alzheimer’s Drugs Market: Opportunity Map

Chapter 4 Market Overview
4.1 Introduction
4.2 Global Alzheimer’s Drugs Market Size (US$ Mn) Forecast, 2015–2025
4.3 Alzheimer’s Drugs Market Outlook 
4.4 Key Industry Events 

Chapter 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis 
5.2 Drivers 
      5.2.1 Increasing global prevalence of Alzheimer’s 
      5.2.2 Improvising regulatory scenario
      5.2.3 Increasing government funding
      5.2.4 Entry of novel symptomatic therapies 
      5.2.5 Growing social awareness of the disease
5.3 Restraints
      5.3.1 Alzheimer’s drug failure rate at 99%
      5.3.2 Multifactorial etiology and complex pathophysiology of the disease
      5.3.3 High level of comorbidity occurring in the elderly population
      5.3.4 Expanding diagnostic capability
      5.3.5 Increasing cost for Alzheimer’s drug development
5.4 Opportunities 
      5.4.1 Reduce the time and risk of AD drug development through an improvement in trial design
      5.4.2 Improving clinical outcomes
5.5 Trends 
      5.5.1 Development of compounds acting on the main stages of the pathogenesis of the disease (disease-modifying agents
      5.5.2 Focused design of multi targeted drugs acting on multiple molecular targets involved in the pathogenesis of the disease
5.6 Porter’s Five Forces Analysis
5.7 PEST Analysis 
5.8 Pipeline Analysis 
5.9 Global Prevalence & Incidence
5.10 Biomarkers Analysis 
5.11 Most Promising Molecules 

Chapter 6 Alzheimer’s Drugs Market Analysis by Drug Class
6.1 Key Findings 
6.2 Introduction 
6.3 Global Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
6.4 Global Alzheimer’s Drugs Market Forecast, by Drug Class 
6.5 Global Alzheimer’s Drugs Market Analysis, by Drug Class 
6.6 Global Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class 
6.7 Key Trends 

Chapter 7 Alzheimer’s Drugs Market Analysis, by Distribution Channel
7.1 Key Findings 
7.2 Introduction 
7.3 Global Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
7.4 Global Alzheimer’s Drugs Market Forecast, by Distribution Channel 
7.5 Global Alzheimer’s Drugs Market Analysis, by Distribution Channel 
7.6 Global Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel 
7.7 Key Trends 

Chapter 8 Alzheimer’s Drugs Market Analysis by Region
8.1 Global Alzheimer’s Drugs Market Snapshot, by Country 
8.2 Global Alzheimer’s Drugs Market Value Share Analysis, by Region 
8.3 Global Alzheimer’s Drugs Market Forecast, by Region 
8.4 Global Alzheimer’s Drugs Market Attractiveness, by Region 

Chapter 9 North America Alzheimer’s Drugs Market Analysis
9.1 Key Findings 
9.2 North America Alzheimer’s Drugs Market Overview 
9.3 North America Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
9.4 North America Alzheimer’s Drugs Market Forecast, by Drug Class
9.5 North America Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
9.6 North America Alzheimer’s Drugs Market Forecast, by Distribution Channel 
9.7 North America Alzheimer’s Drugs Market Value Share Analysis, by Country 
9.8 North America Alzheimer’s Drugs Market Forecast, by Country 
9.9 North America Alzheimer’s Drugs Market Attractiveness Analysis 
9.10 Market Trends 

Chapter 10 Europe Alzheimer’s Drugs Market Analysis
10.1 Key Findings 
10.2 Europe Alzheimer’s Drugs Market Overview 
10.3 Europe Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
10.4 Europe Alzheimer’s Drugs Market Forecast, by Drug Class
10.5 Europe Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
10.6 Europe Alzheimer’s Drugs Market Forecast, by Distribution Channel 
10.7 Europe Alzheimer’s Drugs Market Value Share Analysis, by Country 
10.8 Europe Alzheimer’s Drugs Market Forecast, by Country 
10.9 Europe Alzheimer’s Drugs Market Attractiveness Analysis 
10.10 Market Trends 

Chapter 11 Asia Pacific Alzheimer’s Drugs Market Analysis
11.1 Key Findings 
11.2 Asia Pacific Alzheimer’s Drugs Market Overview 
11.3 Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
11.4 Asia Pacific Alzheimer’s Drugs Market Forecast, by Drug Class
11.5 Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
11.6 Asia Pacific Alzheimer’s Drugs Market Forecast, by Distribution Channel 
11.7 Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Country 
11.8 Asia Pacific Alzheimer’s Drugs Market Forecast, by Country 
11.9 Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis 
11.10 Market Trends 

Chapter 12 Latin America Alzheimer’s Drugs Market Analysis
12.1 Key Findings 
12.2 Latin America Alzheimer’s Drugs Market Overview 
12.3 Latin America Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
12.4 Latin America Alzheimer’s Drugs Market Forecast, by Drug Class
12.5 Latin America Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
12.6 Latin America Alzheimer’s Drugs Market Forecast, by Distribution Channel 
12.7 Latin America Alzheimer’s Drugs Market Value Share Analysis, by Country 
12.8 Latin America Alzheimer’s Drugs Market Forecast, by Country 
12.9 Latin America Alzheimer’s Drugs Market Attractiveness Analysis 
12.10 Market Trends 

Chapter 13 Middle East and Africa (MEA) Alzheimer’s Drugs Market Analysis
13.1 Key Findings 
13.2 Middle East and Africa Alzheimer’s Drugs Market Overview 
13.3 Middle East and Africa Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
13.4 Middle East and Africa Alzheimer’s Drugs Market Forecast, by Drug Class
13.5 Middle East and Africa Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel
13.6 Middle East and Africa Alzheimer’s Drugs Market Forecast, by Distribution Channel 
13.7 Middle East and Africa Alzheimer’s Drugs Market Value Share Analysis, by Country 
13.8 Middle East and Africa Alzheimer’s Drugs Market Forecast, by Country 
13.9 Middle East and Africa Alzheimer’s Drugs Market Attractiveness Analysis 
13.10 Market Trends 

Chapter 14 Company Profiles
14.1 Alzheimer’s Market Share Analysis By Company 
14.2 Competition Matrix 
14.3 Company Profiles
      14.3.1 Allergan plc
               14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.1.2 Product Portfolio
               14.3.1.3 SWOT Analysis
               14.3.1.4 Strategic Overview
      14.3.2 Novartis AG
               14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.2.2 Product Portfolio
               14.3.2.3 SWOT Analysis
               14.3.2.4 Strategic Overview
      14.3.3 Eisai Co Ltd
               14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.3.2 Product Portfolio
               14.3.3.3 SWOT Analysis
               14.3.3.4 Strategic Overview
      14.3.4 Johnson & Johnson
               14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.4.2 Product Portfolio
               14.3.4.3 SWOT Analysis
               14.3.4.4 Strategic Overview
      14.3.5 Daiichi Sankyo Company Limited
               14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.5.2 Product Portfolio
               14.3.5.3 SWOT Analysis
               14.3.5.4 Strategic Overview
      14.3.6 Ono Pharmaceutical Co Ltd
               14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.6.2 Product Portfolio
               14.3.6.3 SWOT Analysis
               14.3.6.4 Strategic Overview
      14.3.7 H Lundbeck A/S
               14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.7.2 Product Portfolio
               14.3.7.3 SWOT Analysis
               14.3.7.4 Strategic Overview
      14.3.8 Merz Holding GmbH & Co KG
               14.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.8.2 Product Portfolio
               14.3.8.3 SWOT Analysis
               14.3.8.4 Strategic Overview

List of Figures

Figure 1: Alzheimer's Drugs Market Snapshot, 2016
Figure 2: DROT Executive Summary
Figure 3: Market Share Executive Summary
Figure 4: Drug Class Revenue Share, 2016
Figure 5: Distribution Channel Revenue Share, 2016
Figure 6: Global Alzheimer's Drugs Market Size (US$ Mn) Forecast, 2015–2025
Figure 7: Market Value Share, by Drug Class (2016
Figure 8: Market Value Share, by Distribution Channel (2016)
Figure 9: Market Value Share, by Region (2016)
Figure 10: Key Industry Events 
Figure 11: Global Alzheimer's Drugs Market Value Share, by Drug Class, 2017 and 2025
Figure 12: Global Cholinergic Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 13: Global Memantine Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 14: Global Combined Drug Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 15: Global Others Drug Class Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 16: Global Alzheimer's Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 17: Global Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 18: Global Hospital Pharmacy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 19: Global Retail Pharmacy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 20: Global Online Sales Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 21: Global Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 22: Global Alzheimer’s Drugs Market Value Share, by Region, 2017 and 2025
Figure 23: Global Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2017–2025
Figure 24: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 25: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017–2025
Figure 26: North America Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
Figure 27: North America Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 28: North America Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
Figure 29: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 30: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 31: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 32: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017–2025
Figure 33: Europe Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
Figure 34: Europe Alzheimer's Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 35: Europe Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
Figure 36: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 37: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 38: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 39: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017-2025
Figure 40: Asia Pacific Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
Figure 41: Asia Pacific Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 42: Asia Pacific Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
Figure 43: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 44: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 45: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 46: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017-2025
Figure 47: Latin America Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
Figure 48: Latin America Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 49: Latin America Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
Figure 50: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 51: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 52: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 53: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017-2025
Figure 54: Middle East & Africa Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
Figure 55: Middle East & Africa Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 56: Middle East & Africa Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
Figure 57: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 58: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 59: Global Alzheimer’s Market Share Analysis By Company (2016)
Figure 60: Allergan plc Breakdown of Net Sales (%), by Business Segment, 2016
Figure 61: Allergan plc Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 62: Novartis Breakdown of Net Sales, by Business segments, 2016
Figure 63: Novartis Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 64: Eisai Breakdown of Net Sales, by Region, 2016
Figure 65: Eisai Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 66: Johnson Breakdown of Net Sales, by Region, 2016
Figure 67: Johnson Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 68: Daiichi Breakdown of Net Sales, by Region, 2016
Figure 69: Daiichi Revenue (US$; Mn) & Y-o-Y Growth (%), 2013–2016
Figure 70: Ono Breakdown of Net Sales, by Region, 2016
Figure 71: Ono Revenue (US$; Mn) & Y-o-Y Growth (%), 2013–2016
Figure 72: Lundbeck Breakdown of Net Sales, by Region 2016
Figure 73: Lundbeck Revenue (US$; Mn) & Y-o-Y Growth (%), 2013–2016
Figure 74: Merz Breakdown of Net Sales, by Region 2016
Figure 75: Merz Revenue (US$; Mn) & Y-o-Y Growth (%), 2013–2016

List of Tables

Table 1: Alzheimer's Drugs: Pipeline Analysis – Phase III
Table 2: Alzheimer's Drugs: Pipeline Analysis – Phase II
Table 3: Alzheimer's Drugs: Pipeline Analysis – Phase I
Table 4: Prevalence and Incidence by Global and Region 
Table 5: Prevalence by Country and Region
Table 6: Biomarker Analysis List in Alzheimer’s Drug Market
Table 7: Most Promising Molecules List
Table 8: Global Alzheimer's Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 9: Global Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 10: Global Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 11: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 12: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 16: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 17: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 18: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 19: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 20: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 21: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 22: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 23: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 24: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025

Global Alzheimer’s Drugs Market: Overview

This report on the Alzheimer’s drugs market analyzes the current and future scenario of the global market. Increasing prevalence of Alzheimer’s, innovation in the development of new drugs, biomarker analysis and most promising molecules analysis, drug class sales during the forecast period.

Global Alzheimer’s Drugs Market: Research Methodology

The global Alzheimer’s drugs market report contain an elaborate executive summary, which includes following points such as market snapshot that provides information about various segments globally. It also comprise information and data analysis of the country’s market with respect to the segments based on drug class type, distribution channels and regions. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises PEST Analysis, Porters Five Forces Analysis and Pipeline Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Alzheimer’s drug market.

Global Alzheimer’s Drugs Market: Segmentation

Based on drug class, the market has been segmented into four major drug class such as cholinergic, memantine, combined drugs, and others. The market segments have been analyzed based on available approved products, cost-effectiveness. All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.

As per distribution channels, the global Alzheimer’s drugs market has been segmented into three segments including hospital pharmacy, retail pharmacy, and online sales. All market segmentations has been analyzed based on increasing demand for disease treatment. Increased patient hospitalization for the treatment of Alzheimer’s are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also comprise the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Geographically, Alzheimer’s drugs market on the basis of region has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been presented for the period from 2015 to 2025. CAGR for all segments has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.

Global Alzheimer’s Drugs Market: Competitive Dynamics

The report also profiles major key players in the Alzheimer’s drugs market based on various attributes such as company overview, product portfolio, financial overview, business strategies, recent developments and company SWOT analysis. Major players operating in the Alzheimer’s drug market included in this report are Allergan plc, Novartis AG, Eisai Co Ltd, H Lundbeck A/S, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co Ltd, Merz Holding GmbH & Co KG, and Johnson & Johnson.

Global Alzheimer’s Drugs Market is segmented as below:

Global Alzheimer’s Drug Market, by Drug Class

  • Cholinergic
  • Memantine
  • Combined Drug
  • Others

Global Alzheimer’s Drug Market, by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

Global Alzheimer’s Drug Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top